Currently out of the existing stock ratings of Annabel Samimy, 273 are a BUY (88.06%), 37 are a HOLD (11.94%).

Annabel Samimy

Work Performance Price Targets & Ratings Chart

Analyst Annabel Samimy, currently employed at STIFEL, carries an average stock price target met ratio of 45.31% that have a potential upside of 40.17% achieved within 333 days.

Annabel Samimy’s has documented 584 price targets and ratings displayed on 40 stocks. The coverage is on Healthcare, Industrials, Technology sectors.

Most recent stock forecast was given on LGND, Ligand Pharmaceuticals at 08-Jul-2026.

Wall Street Analyst Annabel Samimy

Analyst best performing recommendations are on VKTX (VIKING THERAPEUTICS).
The best stock recommendation documented was for EOLS (EVOLUS) at 1/28/2019. The price target of $27 was fulfilled within 10 days with a profit of $12.01 (80.12%) receiving and performance score of 80.12.

Average potential price target upside

of $162.72 (25.25%) on CARA (CARA THERAPEUTIC).
of $56.03 (43.84%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $42.95 (68.2%) on CLSD (CLEARSIDE BIOMEDICAL).

AERI Aerie Pharmaceuticals AGN Allergan plc ANGN Angion Biomedica Corp CALT Calliditas Therapeutics CARA Cara Therapeutic ENDP Endo International PLC EOLS Evolus EVFM Evofem Biosciences FGEN FibroGen HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC MNK Mallinckrodt plc PRGO Perrigo Company PLC RDUS Schnitzer Steel Industries RETA Reata Pharmaceuticals RVNC Revance The TXMD TherapeuticsMD APLS Apellis Pharmaceuticals BHC Bausch Health Companies CLSD Clearside Biomedical SBBP Strongbridge Biopharma plc SUPN Supernus Pharmaceuticals ISEE IVERIC bio RXDX Prometheus Biosciences ZGNX Zogenix PHAS PhaseBio Pharmaceuticals VKTX Viking Therapeutics RANI Rani Therapeutics Holdings IVA Inventiva Sa RGNX Regenxbio TRVI Trevi Therapeutics LGND Ligand Pharmaceuticals PHAT Phathom Pharmaceuticals AER AerCap Holdings NV CLS Celestica GPCR Structure Therapeutics KMDA Kamada MLYS Mineralys Therapeutics OCS Oculis Holding AG ALT Altimmune

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Yigal Nochomovitz (CITI)

Buy Since 19-Dec-2019

$13

4 years 1 months 23 days ago
(29-Aug-2022)

1/6 (16.67%)

$4.7 (56.63%)

176

Please subscribe to see extended stock data

Oren Livnat (HC WAINWRIGHT)

Buy Since 07-Nov-2019

$20

4 years 1 months 28 days ago
(24-Aug-2022)

0/5 (0%)

$14.21 (245.42%)

Please subscribe to see extended stock data

Gregory Fraser

Buy Since 09-Jan-2020

$29

4 years 1 months 28 days ago
(24-Aug-2022)

0/2 (0%)

$14.55 (100.69%)

Please subscribe to see extended stock data

Serge Belanger (NEEDHAM)

Buy Since 17-Sep-2015

$14

4 years 1 months 29 days ago
(23-Aug-2022)

7/19 (36.84%)

$7.75 (124.00%)

211

Please subscribe to see extended stock data

Louise Chen (SCOTIABANK)

Buy Since 22-Oct-2019

$15.25

$62

4 years 1 months 29 days ago
(23-Aug-2022)

1/2 (50%)

$0.09 (0.59%)

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Annabel Samimy most bullish on?

Potential upside of $36.46 has been obtained for LGND (LIGAND PHARMACEUTICALS)

Which stock is Annabel Samimy most reserved on?

Potential downside of $18.12 has been obtained for TRVI (TREVI THERAPEUTICS)

What Year was the first public recommendation made by Annabel Samimy?

On 2009